High-throughput Epitope Mapping of Anti-Viral Antibodies

Information

  • Research Project
  • 8209413
  • ApplicationId
    8209413
  • Core Project Number
    R43AI096936
  • Full Project Number
    1R43AI096936-01
  • Serial Number
    96936
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    8/1/2011 - 13 years ago
  • Project End Date
    7/31/2013 - 11 years ago
  • Program Officer Name
    LI, YEN
  • Budget Start Date
    8/1/2011 - 13 years ago
  • Budget End Date
    7/31/2013 - 11 years ago
  • Fiscal Year
    2011
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/20/2011 - 13 years ago
Organizations

High-throughput Epitope Mapping of Anti-Viral Antibodies

DESCRIPTION (provided by applicant): The identification of highly potent and broadly neutralizing antibodies isolated from HIV-1- infected donors suggests that when presented with a suitable antigenic structure, the human immune system can produce protective antibodies that HIV-1 is unable to evade. Understanding these antigenic structures is a primary objective in developing a vaccine capable of generating broadly protective humoral immunity. Most of these broadly neutralizing MAbs bind conformationally complex epitopes on Envelope that have been difficult to epitope map, and an increasing number of such MAbs are being identified using more efficient approaches to MAb isolation. However, the ability to characterize MAbs has not kept up, leaving a major gap between the growing ability to isolate relevant MAbs and the ability to molecularly define the immunogenic structures that gave rise to them. The goal of this proposal is to develop tools to rapidly and comprehensively map MAb epitopes on structurally complex viral Envelope proteins. Identifying the epitopes of potent and broadly neutralizing MAbs will enable Env variants exhibiting improved antigenic characteristics to be more rapidly designed and tested as vaccine candidates. PUBLIC HEALTH RELEVANCE: This project will contribute to human health by identifying the epitopes of potent and broadly neutralizing MAbs so that Env variants exhibiting improved antigenic characteristics can be more rapidly designed and tested as vaccine candidates.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    242376
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:242376\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    VACC
  • Study Section Name
    HIV/AIDS Vaccines Study Study Section
  • Organization Name
    INTEGRAL MOLECULAR
  • Organization Department
  • Organization DUNS
    034055645
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191045504
  • Organization District
    UNITED STATES